{
  "schemaVersion": 2,
  "eyebrow": "Infectious Diseases",
  "title": "Cellulitis Antibiotic Selection",
  "summary": "Select therapy by first separating nonpurulent cellulitis from abscess-associated infection, then matching route and spectrum to systemic illness, MRSA risk, immune status, source control needs, and clinical response after 48 hours.",
  "seoDescription": "Physician guide to cellulitis antibiotic selection, MRSA coverage, oral versus IV therapy, treatment duration, drainage, and escalation.",
  "clinicalQuestion": "How should clinicians select empiric antibiotics, route, and duration for adults with cellulitis?",
  "specialty": "Infectious Diseases",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "cellulitis antibiotics",
    "nonpurulent cellulitis",
    "purulent cellulitis",
    "MRSA coverage",
    "cephalexin",
    "vancomycin",
    "skin abscess"
  ],
  "keyTakeaways": [
    "Typical nonpurulent cellulitis without systemic signs should receive streptococcal-active therapy; routine MRSA coverage is not indicated solely because cellulitis is present. [15]",
    "Purulence or an abscess changes management: perform incision and drainage and select anti-staphylococcal therapy, including MRSA-active therapy when indicated. [16][1]",
    "Use vancomycin or another agent active against both MRSA and streptococci for severe nonpurulent cellulitis with penetrating trauma, prior or concurrent MRSA, MRSA nasal colonization, injection drug use, or SIRS. [15]",
    "A 5- to 6-day course is appropriate for improving nonpurulent cellulitis; extend treatment when symptoms have not adequately resolved by day 5. [2][14][16]",
    "Initial oral therapy is reasonable for stable patients able to take medications; IV therapy should be reserved for systemic illness, severe disease, inability to take oral therapy, or major host compromise. [1][9]"
  ],
  "sections": [
    {
      "id": "initial-antibiotic-branch",
      "eyebrow": "First decision",
      "heading": "Classify cellulitis before choosing spectrum",
      "intro": "Purulence and severity determine whether treatment is streptococcal-focused, MRSA-active, or broad-spectrum.",
      "paragraphs": [
        "Treat diffuse, nonpurulent cellulitis without systemic signs with an agent active against streptococci. IDSA notes that MRSA is an unusual cause of typical cellulitis; do not add MRSA coverage routinely in an otherwise typical nonpurulent presentation. [15]",
        "Reclassify the episode as purulent when there is purulent drainage, pustules, or an abscess. Staphylococcus aureus, including MRSA, is then a common pathogen, and incision and drainage is primary management when an abscess is present. Obtain a culture from purulent material when feasible if infection is severe, recurrent, or not responding to empiric therapy. [1][16][18]",
        "Escalate beyond routine outpatient selection for systemic signs, SIRS, septic shock, active chemotherapy or other major immunocompromise, or concern for a deeper severe soft-tissue infection. In severely compromised patients, IDSA recommends broad coverage with vancomycin plus piperacillin-tazobactam or cefepime; use local antibiograms to refine empiric therapy. [15][1][20]"
      ],
      "bullets": [
        "Nonpurulent, no systemic signs: select streptococcal-active therapy. [15]",
        "Purulence or abscess: drain when present and cover S. aureus; use MRSA-active therapy when epidemiologically or clinically indicated. [1][16]",
        "Severe nonpurulent disease with MRSA risk factors or SIRS: use an agent active against MRSA and streptococci. [15]",
        "Septic shock or severe immunocompromise: add broad gram-negative and anaerobic coverage to MRSA therapy. [1][15]"
      ],
      "subsections": [],
      "table": {
        "caption": "Antibiotic-selection branches for cellulitis by morphology and severity. [1][15][16]",
        "columns": [
          "Clinical branch",
          "Primary action",
          "Empiric antibiotic direction"
        ],
        "rows": [
          [
            "Typical nonpurulent cellulitis without systemic signs",
            "Outpatient oral therapy if oral intake is reliable. [1][15]",
            "Use streptococcal-active therapy; oral penicillin VK, dicloxacillin, or an oral cephalosporin such as cephalexin are options. [1][15]"
          ],
          [
            "Nonpurulent cellulitis with fever or rigors",
            "Use systemic therapy; reassess need for IV treatment based on illness severity and oral tolerance. [1][15]",
            "Use streptococcal-active therapy; cefazolin or ceftriaxone are IV options cited for patients requiring parenteral treatment. [1]"
          ],
          [
            "Nonpurulent cellulitis with MRSA risk factor or SIRS",
            "Treat as severe nonpurulent cellulitis. [15]",
            "Vancomycin or another agent active against both MRSA and streptococci. [15]"
          ],
          [
            "Purulent cellulitis or abscess",
            "Perform incision and drainage when an abscess is present. [16]",
            "Use MRSA-active therapy when antibiotics are indicated; TMP-SMX, doxycycline, or clindamycin are oral options. [1][16]"
          ],
          [
            "Septic shock or severe immunocompromise",
            "Hospital-level management and broad empiric coverage. [1][15]",
            "Vancomycin plus piperacillin-tazobactam or cefepime. [1][15]"
          ]
        ]
      }
    },
    {
      "id": "oral-regimens",
      "eyebrow": "Outpatient therapy",
      "heading": "Choose oral therapy for stable nonpurulent cellulitis",
      "intro": "For stable patients who can take oral medication, target streptococci first.",
      "paragraphs": [
        "Cephalexin 500 mg orally every 6 hours is a cited regimen for nonpurulent cellulitis. For patients with a severe beta-lactam allergy, clindamycin 300 to 450 mg orally every 6 hours is an alternative, but clindamycin selection should account for local resistance among streptococci and S. aureus and its increased risk of Clostridioides difficile infection. [17][1]",
        "If the presentation is nonpurulent but MRSA risk is present—penetrating trauma, MRSA infection elsewhere, MRSA nasal colonization, injection drug use, or SIRS—use therapy active against both MRSA and streptococci rather than cephalexin alone. [15] A cited oral approach for cellulitis with MRSA risk factors is TMP-SMX 800/160 mg twice daily plus cephalexin 500 mg every 6 hours for 5 days; clindamycin 300 to 450 mg every 6 hours is an alternative when TMP-SMX cannot be used. [17]",
        "For purulent infection or high local MRSA prevalence, oral TMP-SMX, doxycycline, or clindamycin are guideline-supported MRSA-active options. The global pathway lists TMP-SMX 160/800 to 320/1600 mg every 12 hours, doxycycline 100 mg every 12 hours, or minocycline 100 mg every 12 hours for outpatient or step-down therapy in MRSA-risk settings. [1][16]"
      ],
      "bullets": [
        "Cephalexin: 500 mg orally every 6 hours for nonpurulent cellulitis. [17]",
        "Clindamycin: 300 to 450 mg orally every 6 hours when beta-lactams cannot be used; weigh C. difficile risk and local susceptibility. [17][1]",
        "TMP-SMX: 800/160 mg orally twice daily is cited with cephalexin for cellulitis with MRSA risk factors. [17]",
        "Doxycycline: 100 mg orally every 12 hours is an outpatient MRSA-active option for purulent cellulitis or high-MRSA-risk settings. [16]"
      ],
      "subsections": [],
      "table": {
        "caption": "Cited oral regimens and selection considerations. [1][16][17]",
        "columns": [
          "Regimen",
          "When to use",
          "Key limitation or decision point"
        ],
        "rows": [
          [
            "Cephalexin 500 mg every 6 hours",
            "Mild nonpurulent cellulitis requiring streptococcal-active therapy. [17]",
            "Does not address the IDSA-defined MRSA-risk branch. [15]"
          ],
          [
            "Clindamycin 300-450 mg every 6 hours",
            "Alternative for severe beta-lactam allergy; may also provide MRSA activity depending on local susceptibility. [17][1]",
            "Increasing streptococcal and S. aureus resistance and increased C. difficile risk limit use. [1]"
          ],
          [
            "TMP-SMX 800/160 mg twice daily plus cephalexin 500 mg every 6 hours",
            "Cellulitis with MRSA risk factors in the cited regimen. [17]",
            "Use when both MRSA and streptococcal coverage are needed. [15][17]"
          ],
          [
            "Doxycycline 100 mg every 12 hours",
            "Purulent cellulitis or outpatient MRSA-risk setting. [16]",
            "Use within a regimen that addresses the clinical need for streptococcal coverage. [15][16]"
          ]
        ]
      }
    },
    {
      "id": "iv-therapy-and-admission",
      "eyebrow": "Parenteral therapy",
      "heading": "Reserve IV therapy for systemic illness or high-risk hosts",
      "intro": "Route should follow severity and oral tolerance, not lesion size alone.",
      "paragraphs": [
        "For patients with nonpurulent cellulitis who have systemic signs such as fever or rigors and require IV therapy, cited options include cefazolin or ceftriaxone; vancomycin or linezolid are options when MRSA-active therapy is required. [1] IDSA recommends vancomycin or another agent effective against both MRSA and streptococci for severe nonpurulent cellulitis associated with specified MRSA risks or SIRS. [15]",
        "Do not assume IV therapy improves outcomes solely because cellulitis appears extensive. In a multicenter clinical-trial analysis, patients selected for IV treatment more often had CRP greater than 100 mg/L, skin involvement greater than 5% of body surface area, or at least one SIRS criterion; available trials did not demonstrate superiority of IV over oral therapy or benefit from courses longer than 5 days. These markers may identify patients clinicians commonly treat more aggressively but do not independently establish a requirement for IV treatment. [11]",
        "Obtain blood cultures before antibiotics when sepsis is suspected, because pre-antibiotic cultures can permit later de-escalation. Avoid indiscriminate cultures in uncomplicated cellulitis; culture-directed therapy is particularly useful in severe, recurrent, or treatment-nonresponsive infection. [24][18]"
      ],
      "bullets": [
        "Use IV cefazolin or ceftriaxone when systemic nonpurulent cellulitis requires parenteral therapy. [1]",
        "Use vancomycin for severe nonpurulent cellulitis with IDSA-defined MRSA risk factors or SIRS. [15]",
        "For septic shock or severe immunocompromise, use vancomycin plus piperacillin-tazobactam or cefepime. [1][15]",
        "Draw blood cultures before antibiotics when sepsis is suspected. [24]"
      ],
      "subsections": [],
      "table": {
        "caption": "Escalation triggers and parenteral selection. [1][11][15]",
        "columns": [
          "Finding",
          "What it changes",
          "Antibiotic implication"
        ],
        "rows": [
          [
            "Fever or rigors",
            "Signals systemic illness and may justify IV treatment. [1]",
            "Use a parenteral regimen directed at nonpurulent cellulitis pathogens, such as cefazolin or ceftriaxone. [1]"
          ],
          [
            "Penetrating trauma, MRSA elsewhere, MRSA colonization, injection drug use, or SIRS",
            "Moves nonpurulent cellulitis into the severe MRSA-risk branch. [15]",
            "Use vancomycin or another agent active against MRSA and streptococci. [15]"
          ],
          [
            "Septic shock or active chemotherapy/major immunocompromise",
            "Requires broad empiric coverage. [1]",
            "Vancomycin plus piperacillin-tazobactam or cefepime. [1]"
          ],
          [
            "CRP >100 mg/L, skin area >5%, or SIRS score ≥1",
            "Markers associated with clinician use of IV therapy; assess the full clinical context rather than using an isolated threshold. [11]",
            "Do not infer that IV therapy is superior solely from these markers. [11]"
          ]
        ]
      }
    },
    {
      "id": "source-control-and-reassessment",
      "eyebrow": "Treatment failure prevention",
      "heading": "Drain abscesses and reassess response at 48 hours",
      "intro": "Failure to address a drainable collection can make otherwise appropriate antibiotics ineffective.",
      "paragraphs": [
        "When fluctuance, focal purulent drainage, or an abscess accompanies cellulitis, perform incision and drainage as primary management. Antibiotics should be considered in addition to drainage based on disease severity and patient factors; absent drainage is associated with treatment failure in outpatient skin and soft-tissue infection cohorts. [16][1][12]",
        "Use a 5-day treatment course when improvement is evident by day 5; a 5- to 6-day streptococcal-active course is recommended for nonpurulent cellulitis. Extend therapy to 7 to 10 days when symptoms have not resolved at day 5 or when complications develop. [2][14][16]",
        "Reassess patients with minimal improvement by 48 hours. Confirm that the episode was nonpurulent versus abscess-associated, identify whether drainage is needed, review adherence and antibiotic selection, and obtain culture material from purulence when infection is severe, recurrent, or nonresponsive. [17][18]"
      ],
      "bullets": [
        "At 48 hours with minimal improvement: reexamine for a drainable abscess and reconsider MRSA coverage or alternative diagnoses. [17][18]",
        "At day 5 with improvement: stop after a 5- to 6-day total course. [2][14]",
        "At day 5 without adequate resolution: extend treatment up to 7 to 10 days and reassess for complication or source-control failure. [14][16]",
        "For recurrent episodes, identify and correct edema, venous or lymphatic obstruction, toe-web skin breakdown, tinea pedis, obesity, chronic ulcers, and other skin-barrier defects. [14][16]"
      ],
      "subsections": [
        {
          "heading": "Recurrent cellulitis",
          "paragraphs": [
            "Address predisposing factors before suppressive antibiotics: edema from venous or lymphatic obstruction, skin trauma, interdigital cracking or tinea pedis, obesity, and chronic ulcers increase recurrence risk. Oral amoxicillin or intramuscular benzathine penicillin may be considered for recurrent cellulitis, with prophylaxis continued while recurrence-promoting factors persist. [14][16]"
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Response-based actions after antibiotics are started. [2][14][16][17][18]",
        "columns": [
          "Time point",
          "Clinical finding",
          "Next action"
        ],
        "rows": [
          [
            "Baseline",
            "Purulence, fluctuance, or abscess",
            "Incise and drain; obtain a specimen when severe, recurrent, or nonresponsive infection warrants culture-directed therapy. [16][18]"
          ],
          [
            "48 hours",
            "Minimal improvement",
            "Reassess morphology, source control, adherence, and antibiotic spectrum; consider culture when there is purulence or nonresponse. [17][18]"
          ],
          [
            "Day 5",
            "Improving cellulitis",
            "Complete a 5- to 6-day course. [2][14]"
          ],
          [
            "Day 5",
            "Persistent symptoms or complication",
            "Extend therapy up to 7 to 10 days and evaluate for an unresolved abscess or other cause of nonresponse. [14][16]"
          ]
        ]
      }
    },
    {
      "id": "stewardship-pitfalls",
      "eyebrow": "Avoidable errors",
      "heading": "Avoid unnecessary MRSA coverage, prolonged therapy, and superficial cultures",
      "intro": "Stewardship depends on matching treatment intensity to the actual cellulitis phenotype.",
      "paragraphs": [
        "Do not use a presumed high community MRSA rate alone to override the typical nonpurulent cellulitis pathway when there is no purulence or IDSA-defined MRSA risk factor. MRSA is described as an unusual cause of typical cellulitis, whereas abscess-associated infection is usually caused by S. aureus. [15][16]",
        "Avoid routinely extending therapy beyond 5 days in a patient who is improving. International recommendations vary from 5 to 10 to 14 days, but systematic-review evidence found no demonstrated benefit for treatment longer than 5 days in uncomplicated cellulitis. [9][14]",
        "Do not base antibiotic narrowing on a superficial wound culture from intact nonpurulent cellulitis. When microbiology is needed, collect pus from an abscess or wound, tissue, aspirate, or other adequate clinical specimen; severe, recurrent, and nonresponsive disease are the highest-yield situations for culture-directed change. [23][18]"
      ],
      "bullets": [
        "Typical nonpurulent cellulitis: do not reflexively prescribe MRSA-active therapy. [15]",
        "Improving uncomplicated cellulitis: avoid automatically extending antibiotics beyond 5 to 6 days. [2][9][14]",
        "Suspected sepsis: obtain blood cultures before antibiotics; severe or nonresponsive purulent infection: culture the purulent specimen. [24][18]",
        "Use local susceptibility data when selecting empiric MRSA-active therapy, particularly clindamycin. [1][20]"
      ],
      "subsections": [],
      "table": {
        "caption": "Common selection errors and corrective actions. [1][9][15][18][23][24]",
        "columns": [
          "Potential error",
          "Why it matters",
          "Corrective action"
        ],
        "rows": [
          [
            "Adding MRSA coverage to every nonpurulent case",
            "MRSA is unusual in typical cellulitis. [15]",
            "Use streptococcal-active treatment unless purulence or defined MRSA risk changes the branch. [15]"
          ],
          [
            "Treating an abscess with antibiotics alone",
            "Source control is primary management for abscesses. [16]",
            "Perform incision and drainage and add antibiotics when clinically indicated. [16][1]"
          ],
          [
            "Continuing antibiotics past day 5 despite improvement",
            "Available evidence does not show benefit for longer uncomplicated courses. [9][14]",
            "Use a 5- to 6-day course when improving. [2][14]"
          ],
          [
            "Obtaining cultures after antibiotics in suspected sepsis",
            "Delayed cultures can limit de-escalation. [24]",
            "Obtain blood cultures before antimicrobials when sepsis is suspected. [24]"
          ]
        ]
      }
    }
  ],
  "faq": [],
  "references": [
    {
      "number": 1,
      "title": "Advances in the diagnosis and management of skin and soft tissue ...",
      "detail": "www.bmj.com",
      "url": "https://www.bmj.com/content/394/bmj-2026-100580",
      "authors": "www.bmj.com",
      "host": "www.bmj.com"
    },
    {
      "number": 2,
      "title": "Appropriate Use of Short-Course Antibiotics in Common Infections",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/pdf/10.7326/m20-7355",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org"
    },
    {
      "number": 3,
      "title": "Sensitivity of superficial cultures in lower extremity wounds",
      "detail": "shmpublications.onlinelibrary.wiley.com",
      "url": "https://shmpublications.onlinelibrary.wiley.com/doi/abs/10.1002/jhm.688",
      "authors": "shmpublications.onlinelibrary.wiley.com",
      "host": "shmpublications.onlinelibrary.wiley.com"
    },
    {
      "number": 4,
      "title": "Abstracts at CIDSCON 2024 : Journal of Clinical Infectious ... - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cids/fulltext/2024/02030/abstracts_at_cidscon_2024.13.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 5,
      "title": "Complicated and deep bacterial skin and soft tissue ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/ddg.15493",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 6,
      "title": "Diagnostic challenges in differentiating... : Medicine",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/md-journal/fulltext/2018/10260/diagnostic_challenges_in_differentiating.9.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 7,
      "title": "Antimicrobial prescribing guidelines for horses in Australia",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/avj.70003?af=R",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 8,
      "title": "Abstracts : Journal of Clinical Infectious Disease Society - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cids/fulltext/2025/07000/abstracts.10.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 9,
      "title": "Route and duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analysis of the effectiveness and harms of antibiotic treatment",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0163445320305120",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 10,
      "title": "An Update on the Treatment and Management of Cellulitis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1578219019300137",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 11,
      "title": "Antibiotic route and duration of therapy for cellulitis: data extracted from a multi-center clinical trial",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924857920302466",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 12,
      "title": "Empiric Outpatient Therapy with Trimethoprim-Sulfamethoxazole, Cephalexin, or Clindamycin for Cellulitis - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0002934310005656",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 13,
      "title": "CIDSCON 2023 Selected Abstracts : Journal of Clinical ... - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cids/fulltext/2023/01010/cidscon_2023_selected_abstracts.9.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 14,
      "title": "Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5754343",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 15,
      "title": "Skin and Soft Tissue Infections - IDSA",
      "detail": "www.idsociety.org",
      "url": "https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections",
      "authors": "www.idsociety.org",
      "host": "www.idsociety.org"
    },
    {
      "number": 16,
      "title": "WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8761341",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 17,
      "title": "Cellulitis - StatPearls - NCBI Bookshelf - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK549770",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 18,
      "title": "Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6208867",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "1: Antimicrobial Therapy According to Clinical Syndromes",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/aapbooks/book/707/chapter/9238419/Antimicrobial-Therapy-According-to-Clinical",
      "authors": "publications.aap.org",
      "host": "publications.aap.org"
    },
    {
      "number": 20,
      "title": "Treatment of severe skin and soft tissue infections: a review - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6200137",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Methicillin-Resistant Staphylococcus aureus - StatPearls - NCBI - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK482221",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "Red Book 2024-2027 | Systems-Based Treatment Table",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/book/chapter-pdf/1750605/rbo2024_tab.pdf",
      "authors": "publications.aap.org",
      "host": "publications.aap.org"
    },
    {
      "number": 23,
      "title": "7-161",
      "detail": "cdn.clinicaltrials.gov",
      "url": "https://cdn.clinicaltrials.gov/large-docs/18/NCT02607618/Prot_000.pdf",
      "authors": "cdn.clinicaltrials.gov",
      "host": "cdn.clinicaltrials.gov"
    },
    {
      "number": 24,
      "title": "[PDF] Blood Culture Contamination: An Overview for Infection Control and ...",
      "detail": "www.cdc.gov",
      "url": "https://www.cdc.gov/antibiotic-use/core-elements/pdfs/fs-bloodculture-508.pdf",
      "authors": "www.cdc.gov",
      "host": "www.cdc.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Advances in the diagnosis and management of skin and soft tissue ...",
      "detail": "www.bmj.com",
      "url": "https://www.bmj.com/content/394/bmj-2026-100580",
      "authors": "www.bmj.com",
      "host": "www.bmj.com",
      "snippet": "The specific antibiotic should be based on local resistance patterns and antibiograms.1214151628106 For stable patients with non-purulent cellulitis who are able to tolerate oral intake, there are several available antibiotics according to current guidelines.14151628 These include penicillin VK, dic",
      "score": 0.68140936
    },
    {
      "number": 2,
      "title": "Appropriate Use of Short-Course Antibiotics in Common Infections",
      "detail": "www.acpjournals.org",
      "url": "https://www.acpjournals.org/doi/pdf/10.7326/m20-7355",
      "authors": "www.acpjournals.org",
      "host": "www.acpjournals.org",
      "snippet": "In patients with nonpurulent cellulitis, clinicians should use a 5- to 6-day course of antibiotics active against streptococci,",
      "score": 0.533714
    },
    {
      "number": 3,
      "title": "Sensitivity of superficial cultures in lower extremity wounds",
      "detail": "shmpublications.onlinelibrary.wiley.com",
      "url": "https://shmpublications.onlinelibrary.wiley.com/doi/abs/10.1002/jhm.688",
      "authors": "shmpublications.onlinelibrary.wiley.com",
      "host": "shmpublications.onlinelibrary.wiley.com",
      "snippet": "by C Chakraborti · 2010 · Cited by 82 — Superficial wound cultures are routinely used to guide therapy, Cost-effectiveness of blood cultures for adult patients with cellulitis.",
      "score": 0.28862974
    },
    {
      "number": 4,
      "title": "Abstracts at CIDSCON 2024 : Journal of Clinical Infectious ... - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cids/fulltext/2024/02030/abstracts_at_cidscon_2024.13.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Methods: This prospective observational study conducted at Bharati Hospital aimed to investigate CRBSI in hemodialysis patients admitted to the Medicine ICU or wards. Diagnosis followed CDC guidelines, with fever over 101.2°F 48 hours after catheter insertion as a key criterion. Blood samples from b",
      "score": 0.25888813
    },
    {
      "number": 5,
      "title": "Complicated and deep bacterial skin and soft tissue ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/ddg.15493",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "by C Prodinger · 2025 · Cited by 10 — Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy.",
      "score": 0.22877659
    },
    {
      "number": 6,
      "title": "Diagnostic challenges in differentiating... : Medicine",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/md-journal/fulltext/2018/10260/diagnostic_challenges_in_differentiating.9.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "### 3.1 Assessment after admission\n\nThe patient's body temperature was 37.9°C. Slight tenderness without rebound pain was noted at the right upper quadrant. EGD indicated a possible gastric wall abscess (Fig. 3). EUS indicated gastric cellulitis (Fig. 4). The initial clinical diagnosis was a gastric",
      "score": 0.21388613
    },
    {
      "number": 7,
      "title": "Antimicrobial prescribing guidelines for horses in Australia",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/avj.70003?af=R",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "### Chapter 2. Cellulitis\n\n#### Key issues\n\n1. Primary cellulitis is a common condition in general practice and may respond well to empirical antimicrobial therapy, but recurrence or a poor response to treatment should prompt further diagnostic investigation.\n2. Many of the pathogens involved have u",
      "score": 0.2081793
    },
    {
      "number": 8,
      "title": "Abstracts : Journal of Clinical Infectious Disease Society - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cids/fulltext/2025/07000/abstracts.10.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Background: Wound infections significantly contribute to patient morbidity and mortality, often leading to prolonged hospitalizations and elevated healthcare costs. Culturing pus or wound samples plays a crucial role in guiding appropriate antibiotic therapy, thereby helping to minimize the risk of ",
      "score": 0.20277487
    },
    {
      "number": 9,
      "title": "Route and duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analysis of the effectiveness and harms of antibiotic treatment",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0163445320305120",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "therapy receive IV antibiotics and then many remain on them for longer than necessary.10, 11, 12 International recommendations for treatment duration in cellulitis are inconsistent and range from 5 1,13 to 10–14 days,14,15 but in practice durations commonly exceed two weeks.11,12 A recent review add",
      "score": 0.75616
    },
    {
      "number": 10,
      "title": "An Update on the Treatment and Management of Cellulitis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1578219019300137",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Cellulitis is treated with systemic oral or parenteral antibiotics. oral penicillin (250-500 mg twice daily), usually unnecessary in children). adults and",
      "score": 0.7487387
    },
    {
      "number": 11,
      "title": "Antibiotic route and duration of therapy for cellulitis: data extracted from a multi-center clinical trial",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924857920302466",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "## Abstract\n\nIntroduction: Although cellulitis is a relatively common condition, there is uncertainty about the benefit of intravenous (IV) over oral (PO) antibiotic therapy, and the appropriate duration of treatment.\n\nMethods: Data extracted from a clinical trial (NCT01876628) of antibiotic therapy",
      "score": 0.6158511
    },
    {
      "number": 12,
      "title": "Empiric Outpatient Therapy with Trimethoprim-Sulfamethoxazole, Cephalexin, or Clindamycin for Cellulitis - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0002934310005656",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Clinical failure also may partially be explained by the recurrent nature of cellulitis/cutaneous abscess, especially in patients with known risk factors for recurrent SSTIs, such as venous insufficiency, lymphedema, or chronic ulcers. In addition, others have identified that therapy with an antibiot",
      "score": 0.3963491
    },
    {
      "number": 13,
      "title": "CIDSCON 2023 Selected Abstracts : Journal of Clinical ... - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cids/fulltext/2023/01010/cidscon_2023_selected_abstracts.9.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Objectives: Primary Objective: To study Clinical and microbiological profile of patients with IE. Secondary Objective: (1) To determine most common risk factors for IE. (2) To determine rates of MRSA and Fungal IE. (3) To study surgical outcomes in patient with IE. (4) To study the overall outcomes ",
      "score": 0.15637554
    },
    {
      "number": 14,
      "title": "Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5754343",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "penicillin, the recurrence rate decreased only in the patient group without risk factors of cellulitis recurrence . In summary, administering oral amoxicillin or IM benzathine penicillin may be considered as a prophylactic antibiotic for patients with recurrent cellulitis. It is unclear as to how lo",
      "score": 0.6929958
    },
    {
      "number": 15,
      "title": "Skin and Soft Tissue Infections - IDSA",
      "detail": "www.idsociety.org",
      "url": "https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections",
      "authors": "www.idsociety.org",
      "host": "www.idsociety.org",
      "snippet": "3. Typical cases of cellulitis without systemic signs of infection should receive an antimicrobial agent that is active against streptococci (mild; Figure 1) (strong, moderate). For cellulitis with systemic signs of infection (moderate nonpurulent; Figure 1), systemic antibiotics are indicated. Many",
      "score": 0.6415577
    },
    {
      "number": 16,
      "title": "WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8761341",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "##  to the area, and tinea pedis can increase the frequency of recurrences. Addressing these factors may decrease the frequency of recurrences.\n\nThe pathogens involved are streptococci and _S. aureus_. Cellulitis associated with abscesses is usually caused by _S. aureus_. In contrast, typical (non-p",
      "score": 0.608897
    },
    {
      "number": 17,
      "title": "Cellulitis - StatPearls - NCBI Bookshelf - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK549770",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "In patients with purulent cellulitis, MRSA colonization, cellulitis associated with an abscess or extensive puncture wounds, or a history of intravenous drug use, patients should receive antibiotics that treat MRSA as well. Cellulitis with MRSA risk factors should be treated with trimethoprim-sulfam",
      "score": 0.5463757
    },
    {
      "number": 18,
      "title": "Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6208867",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Systemic antibiotic therapy against the causative pathogen remains the mainstay for treatment of cSSTIs. Antibiotics against _S. aureus_ are recommended for all cases involving systemic presentations such as temperature >38°C or <36°C, tachypnea (>24 breaths per minute), tachycardia (>90 beats per m",
      "score": 0.5158888
    },
    {
      "number": 19,
      "title": "1: Antimicrobial Therapy According to Clinical Syndromes",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/aapbooks/book/707/chapter/9238419/Antimicrobial-Therapy-According-to-Clinical",
      "authors": "publications.aap.org",
      "host": "publications.aap.org",
      "snippet": "Because nonsuppurative cellulitis is most often caused by group A streptococcus, cephalexin alone is usually effective.",
      "score": 0.43669468
    },
    {
      "number": 20,
      "title": "Treatment of severe skin and soft tissue infections: a review - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6200137",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "44..\n   45..\n   46..\n   47.. Arakaki, Strazzula, Woo, Kroshinsky. The impact of dermatology consultation on diagnostic accuracy and antibiotic use among patients with suspected cellulitis seen at outpatient internal medicine offices: a randomized clinical trial. _JAMA Dermatol_ 2014; 150:1056–1061. ",
      "score": 0.40147716
    },
    {
      "number": 21,
      "title": "Methicillin-Resistant Staphylococcus aureus - StatPearls - NCBI - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK482221",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "## Treatment / Management\n\nThe selection of empirical antibiotic therapy for treating MRSA infections depends on the type of disease, local S aureus resistance patterns, drug availability, adverse-effect profile, and individual patient characteristics.(#article-25074.r27)(#article-25074.r28)(#articl",
      "score": 0.22576675
    },
    {
      "number": 22,
      "title": "Red Book 2024-2027 | Systems-Based Treatment Table",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/book/chapter-pdf/1750605/rbo2024_tab.pdf",
      "authors": "publications.aap.org",
      "host": "publications.aap.org",
      "snippet": "Duration of therapy is regardless of whether vascular catheter is removed, and should not be extended solely based on presence of antibiotic.",
      "score": 0.036456086
    },
    {
      "number": 23,
      "title": "7-161",
      "detail": "cdn.clinicaltrials.gov",
      "url": "https://cdn.clinicaltrials.gov/large-docs/18/NCT02607618/Prot_000.pdf",
      "authors": "cdn.clinicaltrials.gov",
      "host": "cdn.clinicaltrials.gov",
      "snippet": "0 to 3 (0=none, 1=mild, 2=moderate, or 3=severe). 7.6.1.2.3 Microbiology Assessment An adequate clinical specimen for microbiologic evaluation (eg, pus from a wound or abscess, an aspirate or skin biopsy specimen from the leading edge of cellulitis) will be obtained at baseline prior to randomizatio",
      "score": 0.518815
    },
    {
      "number": 24,
      "title": "[PDF] Blood Culture Contamination: An Overview for Infection Control and ...",
      "detail": "www.cdc.gov",
      "url": "https://www.cdc.gov/antibiotic-use/core-elements/pdfs/fs-bloodculture-508.pdf",
      "authors": "www.cdc.gov",
      "host": "www.cdc.gov",
      "snippet": "and the Clinical Laboratory Standards Institute (CLSI) have recommended that an overall blood culture contamination rate should not exceed 3%5. However, many facilities have been able to drive this to less than 1%. Therefore, it should be possible to achieve blood culture contamination rates substan",
      "score": 0.25170332
    }
  ],
  "publishedAt": "2026-09-15T21:09:42.154733+00:00",
  "updatedAt": "2026-09-15T21:09:42.154733+00:00",
  "readingMinutes": 6,
  "slug": "cellulitis-antibiotic-selection"
}